Brown Capital Management's Q2 2024 investor letter discusses the underperformance of their Mid Company Fund, highlighting Teladoc Health, Inc. as a key stock. Teladoc showed promising returns despite revenue decline, with focus shifting towards AI stocks for higher returns.